GE Expands SF6-free High-Voltage Product Portfolio to Help Cut Global Greenhouse Gas Emissions
GE Renewable Energy’s Grid Solutions business (NYSE:GE) today announced plans to invest tens of millions of dollars to expand its range of sulfur hexafluoride (SF6)-free high-voltage substation equipment to include all key high-voltage levels by 2025. This is one of Grid Solution’s biggest portfolio investments in years and will support customers in their efforts to reduce greenhouse gas emissions. GE is the leader in SF6-free high-voltage solutions with its Green Gas for Grid, or g3 (pronounced “g”- cubed) offering. g3 products feature the same high performance and compact dimensional footprint as traditional products, but with more than a 99% reduced global warming potential (GWP).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190926005188/en/
g3 gas-insulated substation at Denmark’s Cerius (Photo: Business Wire)
To transmit electricity safely across the grid from point of generation to the end consumer, substations are used to help transform voltage levels from high to low or vice-versa, and to secure and dispatch the power flow. Due to its strong insulating properties, SF6 is widely used in substation equipment such as switchgear and instrument transformers, with the transmission industry accounting for approximately 80% of the world’s usage. However, this potent greenhouse gas is estimated to contribute 23,500 times more emissions than CO₂ in the event of a leakage and can remain in the atmosphere for up to 3,200 years.
Eighteen of the 19 warmest years on record have occurred since 2001, driven in large part by greenhouse gases. By offering SF6-free solutions, GE is actively helping customers and countries meet their goals to drastically reduce emissions set by the Paris Climate Agreement as a global response to curb the impact of climate change and limit the overall planet’s warming to well below 2 degrees Celsius.
“We believe it is our responsibility to lead by example,” said Reinaldo Garcia, CEO of GE’s Grid Solutions. “It is critical for us to advance tangible solutions to minimize greenhouse gas emissions. I am proud that g3 is one of the leading solutions in the Grid Solutions’ portfolio to help our customers navigate this journey to lower emissions.”
By 2025, GE’s Grid Solutions will offer SF6-free gas-insulated substations up to 420 kV, dead tank and live tank circuit breakers up to 550 kV, as well as instrument transformers up to 420 kV. To see GE’s planned g3 portfolio until 2025, click here. Currently, GE’s g3 products are type-tested and available for live tank circuit breakers and gas-insulated substations up to 145 kV, gas-insulated lines (GIL) up to 420 kV and instrument transformers up to 245 kV.
“GE has been at the forefront of developing new technologies that will help transform the electric transmission and distribution industry and also help our customers positively impact the communities around them,” said Vera Silva, Chief Technology Officer at GE’s Grid Solutions. “By expanding our g3 offering to all key high-voltage applications, we’re helping businesses meet and act on the environmental challenges facing our planet.”
Since the first pilot installation of a g3 420-kV GIL by UK’s National Grid in 2017, 15 other leading utilities have chosen GE’s g3 equipment such as Scotland’s SPEN and SSEN, Switzerland’s Axpo, France’s RTE and Germany’s TenneT. By adopting this industry-leading SF6-free technology early on, these 16 utilities have avoided the installation of more than 386,000 tons of CO2 equivalent on the grid.
For more information on GE’s high-voltage g3 substation equipment, visit our website.
Click here for GE’s g3 interactive application.
Notes to Editors:
About GE Renewable Energy
GE Renewable Energy is a $15 billion business which combines one of the broadest portfolios in the renewable energy industry to provide end-to-end solutions for our customers demanding reliable and affordable green power. Combining onshore and offshore wind, blades, hydro, storage, utility-scale solar, and grid solutions as well as hybrid renewables and digital services offerings, GE Renewable Energy has installed more than 400+ gigawatts of clean renewable energy and equipped more than 90 percent of utilities worldwide with its grid solutions. With nearly 40,000 employees present in more than 80 countries, GE Renewable Energy creates value for customers seeking to power the world with affordable, reliable and sustainable green electrons.
About GE’s Grid Solutions
Grid Solutions, a GE Renewable Energy business, serves customers globally with over 17,000 employees in approximately 80 countries. Grid Solutions helps enable utilities and industry to effectively manage electricity from the point of generation to the point of consumption, helping to maximize the reliability, efficiency and resilience of the grid. For more about GE Renewable Energy’s Grid Solutions business, visit https://www.gegridsolutions.com/
For more information, contact:
GE Renewable Energy, Grid Solutions business
+33 (0)6 22 56 07 46
For more information, contact:
Allison J. Cohen
GE Renewable Energy, Grid Solutions business
External Communications Manager
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Post Malone and Crocs Launch Fourth Collaboration9.12.2019 20:57:00 EET | Press release
Crocs, Inc. (NASDAQ: CROX), a global leader in innovative, casual footwear for women, men and children, today announced their latest product collaboration with multi-platinum recording artist Post Malone. This ground-breaking fourth installment of the Post Malone x Crocs collaboration series features the Post Malone x Crocs Duet Max Clog, an innovative clog silhouette with a unique blue and black urban camo pattern, an exaggerated chunky outsole and pivotable backstraps with adjustable hook and loop closures. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005664/en/ The Post Malone x Crocs Duet Max Clog is an innovative clog silhouette with a unique blue and black urban camo pattern, an exaggerated chunky outsole and pivotable backstraps with adjustable hook and loop closures. This is the fourth collaboration between the duo. (Photo: Business Wire) The evolution of the Post Malone x Crocs partnership is evident over th
Knopp Biosciences Presents Data Further Characterizing Its Lead Kv7.2 Activator Drug Candidate for the Treatment of KCNQ2 Epileptic Encephalopathy at the American Epilepsy Society’s 2019 Annual Meeting9.12.2019 20:00:00 EET | Press release
Knopp Biosciences LLC, a privately held drug discovery and development company focused on delivering breakthrough treatments for immunological and neurological diseases with high unmet need, today presented data characterizing KB-3061, the lead molecule in the Company’s Kv7 ion channel platform, at the American Epilepsy Society’s (AES) 2019 Annual Meeting in Baltimore, Maryland. Knopp is advancing the development of KB-3061 as a potential precision medicine treatment for the rare, neonatal disease KCNQ2 epileptic encephalopathy (KCNQ2-EE), a genetically defined disease associated with seizures beginning in the first days of life and profound neurodevelopmental delay. The disease is caused by dominant-negative mutations in the KCNQ2 gene, which produces a potassium channel, Kv7.2, critical to early brain development. Data presented at AES by Knopp scientists and its academic collaborators support the continued development of KB-3061 as a potential treatment for children with KCNQ2-EE. K
Murray Energy Corporation Posts Information to its Website Related to Murray Metallurgical9.12.2019 18:46:00 EET | Press release
Beginning on December 2, 2019, Murray Energy Corporation (the “Company”) engaged in confidential discussions under separate confidentiality agreements with certain members of an ad hoc group of superpriority lenders related Murray Metallurgical Coal Holdings, LLC and its subsidiaries (collectively, “Murray Metallurgical”). The confidentiality agreements require the Company to publicly disclose all material non-public information provided to such lenders on or prior to 8:30am (New York time) on December 9, 2019. The Company has posted certain previously undisclosed material to its website to satisfy its disclosure obligations under the confidentiality agreements. Such information can be viewed at the Investors portion of the Company’s website, located at murrayenergycorp.com/investors. Further inquiries should be directed to email@example.com. Safe Harbor Statement The materials referenced in this release and posted to our website include forward-looking statements. A variety of fact
Seattle Genetics and Takeda Announce Additional Analyses of ADCETRIS® (Brentuximab Vedotin) ECHELON-1 and ECHELON-2 Phase 3 Clinical Trials at the 2019 ASH Annual Meeting9.12.2019 18:00:00 EET | Press release
Seattle Genetics, Inc. (Nasdaq:SGEN) and Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) today announced additional analyses of results from the ECHELON-1 and ECHELON-2 frontline phase 3 trials of ADCETRIS® (brentuximab vedotin). These analyses were presented at the 61st Annual Meeting of the American Society of Hematology (ASH) taking place December 7-10, 2019 in Orlando, Fla. ADCETRIS is an antibody-drug conjugate (ADC) directed to CD30, a defining marker of classical Hodgkin lymphoma and expressed on the surface of several types of peripheral T-cell lymphomas (PTCL). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191209005169/en/ The ECHELON-1 analysis highlighted a four-year update of the phase 3 clinical trial in a poster presentation. ECHELON-1 is evaluating ADCETRIS in combination with AVD (Adriamycin [doxorubicin], vinblastine and dacarbazine) compared to ABVD (Adriamycin [doxorubicin], bleomycin, vinblasti
Takeda Demonstrates Its Long-Standing Commitment to Advancing Treatments for Rare Bleeding Disorders with Studies Highlighting Real-World Evidence and Investigational Gene Therapy at ASH 20199.12.2019 18:00:00 EET | Press release
Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE:TAK) (“Takeda”), today presented nine hematology poster presentations at the 61st American Society of Hematology (ASH) Annual Meeting that underscore its commitment to advancing treatments for rare bleeding disorders by incorporating real-world data and developing innovative adeno-associated virus (AAV) gene therapies. Understanding Real-World Evidence to Advance Patient-Centric Innovation in Bleeding Disorders Real-world evidence from studies across many of Takeda’s portfolio of treatments for hemophilia demonstrate the cost savings and patient benefits resulting from ongoing personalized treatment. However, in von Willebrand disease, real-world evidence highlights the ongoing unmet clinical need for personalization, as it may enable improved treatment outcomes. Insights presented at ASH include: ADYNOVATE ® [Antihemophilic Factor (Recombinant), PEGylated]: In the poster “Real-World Age-Stratified FVIII Consumption and Bleed Outcom
Altasciences to Conduct Clinical Trial for Opioid Use Disorder Under NIH Funding9.12.2019 17:39:00 EET | Press release
Altasciences has been selected by Indivior PLC to conduct "A Phase I, Double-Blind, Placebo-Controlled, Randomized, Single Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of INDV-2000 (C4X_3256) Under Fasting and Fed Conditions in Healthy Volunteers", pursuant to the National Institutes of Health (NIH) Funding Opportunity Announcement RFA-DA-19-002, dedicated to the development of medications to prevent and treat opioid use disorder and overdose. The grant was made to Indivior by the NIH in fiscal year 2019, to apply scientific solutions to reverse the national opioid crisis. In March 2018, Indivior entered into a license agreement with C4X Discovery Holdings PLC (C4X) whereby Indivior obtained exclusive global rights to develop and commercialize INDV-2000 (C4X_3256). The first-in-human, single-ascending-dose study will be conducted in two parts — Part I: double-blind, placebo-controlled, randomized, single-ascending-dose study in fasted condition. Part II:
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom